RESUMO
Essential thrombocythemia (ET) is a chronic myeloproliferative syndrome characterized by thrombocythemia and increased megakaryocytes in bone marrow, thrombosis and/or hemorrhagic manifestations. We report here a ten-year experience in the treatment of ET with anagrelide (A), a non mutagenic drug that inhibits megakaryocyte maturation. Between April 1991 and June 2001, 54 ET patients were included with platelet counts > 900 x 10(9)/l in asymptomatic cases and > 600 x 10(9)/l in symptomatic ones. Age at diagnosis was 39 years (11-83). Previously 30 patients had received treatment with hydroxyurea, alpha INF, busulfan and/or 32P. At diagnosis 18 patients had microvascular obstruction, 7 thrombosis, 8 hemorrhagic manifestations and 3 both hemorrhage and thrombosis. Platelet counts at diagnosis were 1200 x 10(9)/l (600-3472) and before A 995 x 10(9)/l (520-2206). The follow-up from diagnosis was 68 months (9-172) and with A treatment 34 months (2-100). The A dose during the first week of treatment was 2.5 mg/d (1-3) and at maintenance 1.5 mg/d (1-3). Complete response was obtained in 96.3 cases, 77 with platelet counts < 400 x 10(9)/l, and 18.5 < 600 x 10(9)/l. The median time to obtain a complete response was 14 days. Transient adverse effects were present in 66 of patients (headache, nausea, abdominal distention, palpitation and edema). Mild to moderate anemia developed within 2-8 months in 40 of patients. During treatment 8 patients had microvascular obstruction with platelet counts over 400 x 10(9)/l and 7 with normal values. One patient developed myelofibrosis. Five patients died for reasons unrelated to ET. In conclusion, anagrelide was effective in reducing platelet counts and preventing mayor thrombotic events (AU)#S#a